Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Identifieur interne : 002039 ( Main/Merge ); précédent : 002038; suivant : 002040Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Auteurs : Olivier Rascol [France] ; Santiago Perez-LloretSource :
- Expert opinion on pharmacotherapy [ 1744-7666 ] ; 2009.
English descriptors
- KwdEn :
- Administration, Cutaneous, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Controlled Clinical Trials as Topic, Disorders of Excessive Somnolence (chemically induced), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dose-Response Relationship, Drug, Humans, Nausea (chemically induced), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), PubMed, Tetrahydronaphthalenes (administration & dosage), Tetrahydronaphthalenes (adverse effects), Tetrahydronaphthalenes (therapeutic use), Thiophenes (administration & dosage), Thiophenes (adverse effects), Thiophenes (therapeutic use), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Dopamine Agonists, Tetrahydronaphthalenes, Thiophenes.
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Tetrahydronaphthalenes, Thiophenes.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Tetrahydronaphthalenes, Thiophenes.
- chemically induced : Disorders of Excessive Somnolence, Nausea.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Administration, Cutaneous, Controlled Clinical Trials as Topic, Dose-Response Relationship, Drug, Humans, PubMed, Treatment Outcome.
Abstract
Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption in unneeded, constant drug delivery, and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications.
DOI: 10.1517/14656560902746041
PubMed: 19239399
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C11
- to stream PubMed, to step Curation: 000B71
- to stream PubMed, to step Checkpoint: 000B71
- to stream Ncbi, to step Merge: 000973
- to stream Ncbi, to step Curation: 000973
- to stream Ncbi, to step Checkpoint: 000973
Links to Exploration step
pubmed:19239399Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rotigotine transdermal delivery for the treatment of Parkinson's disease.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France. rascol@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19239399</idno><idno type="pmid">19239399</idno><idno type="doi">10.1517/14656560902746041</idno><idno type="wicri:Area/PubMed/Corpus">000C11</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C11</idno><idno type="wicri:Area/PubMed/Curation">000B71</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B71</idno><idno type="wicri:Area/PubMed/Checkpoint">000B71</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B71</idno><idno type="wicri:Area/Ncbi/Merge">000973</idno><idno type="wicri:Area/Ncbi/Curation">000973</idno><idno type="wicri:Area/Ncbi/Checkpoint">000973</idno><idno type="wicri:Area/Main/Merge">002039</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rotigotine transdermal delivery for the treatment of Parkinson's disease.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France. rascol@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="eISSN">1744-7666</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Controlled Clinical Trials as Topic</term><term>Disorders of Excessive Somnolence (chemically induced)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Nausea (chemically induced)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>PubMed</term><term>Tetrahydronaphthalenes (administration & dosage)</term><term>Tetrahydronaphthalenes (adverse effects)</term><term>Tetrahydronaphthalenes (therapeutic use)</term><term>Thiophenes (administration & dosage)</term><term>Thiophenes (adverse effects)</term><term>Thiophenes (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agonists</term><term>Tetrahydronaphthalenes</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Tetrahydronaphthalenes</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Tetrahydronaphthalenes</term><term>Thiophenes</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Disorders of Excessive Somnolence</term><term>Nausea</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Controlled Clinical Trials as Topic</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>PubMed</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption in unneeded, constant drug delivery, and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002039 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002039 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:19239399
|texte= Rotigotine transdermal delivery for the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:19239399" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |